Abstract: A system and method for producing a near-infrared sensitive luminescent materials beyond 1000 nm is disclosed. The method includes reacting K2[PtCl4] and cyanoxime ligands in an aqueous solution to achieve dark-green one-dimensional coordination-polymeric materials having a molecular formula of PtL2, wherein L are the cyanoxime ligands having a molecular formula of NC—C(?NOH)—R with R being an electron withdrawing group such as: N?N-diethylacetamide, N-piperidine, N-morpholyl, 2-pyridine, benzoyl, or N-pyrrolidine.

Abstract: A system and method for producing a near-infrared sensitive luminescent materials beyond 1000 nm is disclosed. The method includes reacting K2[PtCl4] and cyanoxime ligands in an aqueous solution to achieve dark-green one-dimensional coordination-polymeric materials having a molecular formula of PtL2, wherein L are the cyanoxime ligands having a molecular formula of NC—C(?NOH)—R with R being an electron withdrawing group such as: N?N-diethylacetamide, N-piperidine, N-morpholyl, 2-pyridine, benzoyl, or N-pyrrolidine.

Abstract: Silver(I) cyanoximates of AgL composition (L=NC—C(NO)—R, where R is electron withdrawing groups: —CN, —C(O)NR2, —C(O)R? (alkyl), —C(O)OEt, 2-heteroaryl fragments such as 2-pyridyl, 2-benzimidazolyl, 2-benzoxazolyl, 2-benzthiazolyl) are synthesized and characterized using spectroscopic methods and X-ray analysis. The synthesized compounds also demonstrate remarkable insensitivity toward visible light and UV-radiation. The combined characteristics of these compounds, such as light insensitivity, poor water solubility, high thermal stability, lack of toxicity of organic ligands, and antimicrobial activity make these silver(I) cyanoximates compounds suitable for use in biomaterial and medical devices.

Abstract: Compositions of matter for treating cancer patients are used to prevent or limit cardiotoxicity during or after treatment with anthracycline drugs, and to prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Preferred embodiments comprise a pharmaceutical composition comprising compounds having halogenated (or pseudo-halogenated) aryl groups, preferably halogenated (or pseudo-halogenated) arylcyanooximes or phenylcyanooximes and derivatives or analogs thereof, including those comprising —CL or —F, or other substituents on an aryl/phenyl ring. The preferred composition of arylcyanooxime(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately from the at least one anthracycline compound.

Abstract: Compositions of matter and methods of treating cancer patients are used to prevent or limit cardiotoxicity during or after cancer treatment with anthracycline drugs, and to prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with a pharmaceutical composition comprising compounds having halogenated (or pseudo-halogenated) aryl groups, preferably halogenated (or pseudo-halogenated) arylcyanooximes or phenylcyanooximes and derivatives or analogs thereof, including those comprising —CL or —F, or other substituents on an aryl/phenyl ring.

Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.

Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.

Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.

Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.

Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.